Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hikaru Ota

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Journal of Clinical Medicine|May 14, 2025
Pneumatic Displacement and Anti-VEGF Therapy for Submacular Hemorrhage in Neovascular Age-Related Macular Degeneration: A Retrospective StudyHikaru Ota, Jun Takeuchi, Ryo Nonogaki, et al.
Japanese Journal of Ophthalmology|June 11, 2025
Efficacy of switching from existing anti-vascular endothelial growth factor drugs to ranibizumab biosimilar in neovascular age-related macular degenerationHikaru Ota, Jun Takeuchi, Ryo Nonogaki, et al.
The Journal of Physical Chemistry. B|March 7, 2023
Cholesterol as a Subsidiary Component of Sorbitan Surfactant-Based Aggregates: A Study of Formation, Hydrophobicity, and Estimation of Localization of Embedded MoleculesKeita Hayashi, Hikaru Ota, Haruna Sugimura, et al.
Graefe'S Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie|May 17, 2024
Five-year outcomes of treat and extend regimen using intravitreal aflibercept injection for treatment-naïve age-related macular degenerationHikaru Ota, Keiko Kataoka, Keiko Asai, et al.
Langmuir : the ACS Journal of Surfaces and Colloids|June 22, 2026
Microfluidic System for Continuous Triacylglycerol Supply with Ethanol as a Cosolvent to Artificial Organelle ModelsKeita Hayashi, Toku Adachi, Hikaru Ota, et al.
Investigative Ophthalmology & Visual Science|September 9, 2024
Aqueous Humor Cytokine Analysis in Age-Related Macular Degeneration After Switching From Aflibercept to FaricimabTakahito Todoroki, Jun Takeuchi, Hikaru Ota, et al.
Japanese Journal of Ophthalmology|March 2, 2022
Switching from aflibercept to brolucizumab for the treatment of refractory neovascular age-related macular degenerationHikaru Ota, Jun Takeuchi, Yuyako Nakano, et al.
Retina (Philadelphia, Pa.)|February 2, 2023
LONG-TERM MORPHOLOGIC CHANGES IN MACULAR NEOVASCULARIZATION UNDER AFLIBERCEPT TREATMENT WITH A TREAT-AND-EXTEND REGIMENYuyako Nakano, Jun Takeuchi, Etsuyo Horiguchi, et al.
Graefe'S Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie|March 7, 2023
Predictive factors for outcomes of half-dose photodynamic therapy combined with aflibercept for pachychoroid neovasculopathyJun Takeuchi, Hikaru Ota, Yuyako Nakano, et al.
Scientific Reports|December 31, 2024
Analysis of the aqueous humor before and after the administration of faricimab in patients with nAMDRyo Nonogaki, Hikaru Ota, Jun Takeuchi, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Journal of Clinical Medicine|May 14, 2025
Pneumatic Displacement and Anti-VEGF Therapy for Submacular Hemorrhage in Neovascular Age-Related Macular Degeneration: A Retrospective StudyHikaru Ota, Jun Takeuchi, Ryo Nonogaki, et al.
Japanese Journal of Ophthalmology|June 11, 2025
Efficacy of switching from existing anti-vascular endothelial growth factor drugs to ranibizumab biosimilar in neovascular age-related macular degenerationHikaru Ota, Jun Takeuchi, Ryo Nonogaki, et al.
The Journal of Physical Chemistry. B|March 7, 2023
Cholesterol as a Subsidiary Component of Sorbitan Surfactant-Based Aggregates: A Study of Formation, Hydrophobicity, and Estimation of Localization of Embedded MoleculesKeita Hayashi, Hikaru Ota, Haruna Sugimura, et al.
Graefe'S Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie|May 17, 2024
Five-year outcomes of treat and extend regimen using intravitreal aflibercept injection for treatment-naïve age-related macular degenerationHikaru Ota, Keiko Kataoka, Keiko Asai, et al.
Langmuir : the ACS Journal of Surfaces and Colloids|June 22, 2026
Microfluidic System for Continuous Triacylglycerol Supply with Ethanol as a Cosolvent to Artificial Organelle ModelsKeita Hayashi, Toku Adachi, Hikaru Ota, et al.
Investigative Ophthalmology & Visual Science|September 9, 2024
Aqueous Humor Cytokine Analysis in Age-Related Macular Degeneration After Switching From Aflibercept to FaricimabTakahito Todoroki, Jun Takeuchi, Hikaru Ota, et al.
Japanese Journal of Ophthalmology|March 2, 2022
Switching from aflibercept to brolucizumab for the treatment of refractory neovascular age-related macular degenerationHikaru Ota, Jun Takeuchi, Yuyako Nakano, et al.
Retina (Philadelphia, Pa.)|February 2, 2023
LONG-TERM MORPHOLOGIC CHANGES IN MACULAR NEOVASCULARIZATION UNDER AFLIBERCEPT TREATMENT WITH A TREAT-AND-EXTEND REGIMENYuyako Nakano, Jun Takeuchi, Etsuyo Horiguchi, et al.
Graefe'S Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie|March 7, 2023
Predictive factors for outcomes of half-dose photodynamic therapy combined with aflibercept for pachychoroid neovasculopathyJun Takeuchi, Hikaru Ota, Yuyako Nakano, et al.
Scientific Reports|December 31, 2024
Analysis of the aqueous humor before and after the administration of faricimab in patients with nAMDRyo Nonogaki, Hikaru Ota, Jun Takeuchi, et al.
Pageof 2